Therma Bright Congratulates John Patton, PhD of InStatin on Receiving the Prestigious Charles G. Thiel Award
Therma Bright Congratulates John Patton, PhD of InStatin on Receiving the Prestigious Charles G. Thiel Award
Chairman of Therma Bright's Strategic Investment Partner Recognized for Outstanding Research and Discovery in Respiratory Drug Delivery
Therma Bright的战略投资合作伙伴主席因呼吸道药物传递方面的杰出研究与发现而受到表彰
Toronto, Ontario--(Newsfile Corp. - September 4, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in cutting-edge diagnostic and medical device technologies, extends its congratulations to strategic investment partner InStatin's John Patton, Ph.D on receiving the prestigious Charles G. Thiel Award for outstanding research and discovery in respiratory drug delivery (RDD).
安大略省多伦多--(资讯公司新闻-2024年9月4日)- Therma Bright公司(TSXV: THRM)(OTCQB: TBRIF)("Therma"或"公司"),一家专注于先进诊断和医疗器械技术的开发商和投资合作伙伴,向战略投资合作伙伴InStatin的John Patton博士致以诚挚的祝贺,因其在呼吸道药物传递(RDD)方面的杰出研究与发现而获得享负盛名的Charles G. Thiel奖。
John Patton, Ph.D, a renowned biotechnology scientist, Chairman of InStatin and Head of the Scientific Advisory Board (SAB) for global leader Kindeva Drug Delivery (KDD), was honored at the Respiratory Drug Delivery Conference. The Charles G. Thiel Award, presented every two years by fellow scientists during the Conference, recognizes one individual for their pioneering and significant advancements in the science and technology of respiratory drug delivery.
著名生物技术科学家、InStatin主席兼全球领先的Kindeva Drug Delivery (KDD)科学顾问委员会(SAB)主席John Patton博士在呼吸道药物传递大会上受到嘉奖。Charles G. Thiel奖每两年在大会期间由同行科学家颁发,以表彰一个个人在呼吸道药物传递科学技术上的开创性和重大进展。
Before InStatin, John held senior leadership roles and served on the boards of several prominent companies. He co-founded Inhale/Nektar (NKTR) in 1990, which achieved a $2.1 billion NASDAQ valuation and received global approval for the first inhaled insulin with Pfizer, which won the Wall Street Journal's Medical Innovation of the Year in 2006. He also co-founded Halozyme (HALO) in 1999 and served on its board until 2015; Today, Halozyme has a market cap of $8.08 billion. Additionally, John founded and led Dance Biopharm (now Aerami Therapeutics) from 2009 to 2018 and co-founded InCarda Therapeutics, which focuses on inhaled treatments for acute cardiac conditions. His career includes multiple successful mergers and acquisitions, as well as receiving numerous honors, publishing articles and research in over 100 publications, and securing more than 45 patents.
在InStatin之前,John曾担任多家知名公司的高级领导职务,并担任董事会成员。他于1990年共同创立了Inhale/Nektar(NKTR),该公司达到21亿美元的纳斯达克估值,并与辉瑞公司获得了全球首个吸入胰岛素的批准,该产品于2006年荣获《华尔街日报》年度医疗创新奖。他还于1999年共同创立了Halozyme(HALO)并担任董事会成员,直至2015年;如今,Halozyme的市值为80.8亿美元。此外,John还于2009年至2018年创立并领导了Dance Biopharm(现Aerami Therapeutics),还共同创立了InCarda Therapeutics,该公司专注于治疗急性心脏病的吸入治疗。他的职业生涯包括多次成功的合并收购,以及获得多项荣誉、在100多种刊物上发表文章和研究,并获得了45项以上的专利。
"We are thrilled to congratulate John on this well-deserved and prestigious award for his remarkable contributions to respiratory drug delivery (RDD) systems," said Rob Fia, CEO of Therma Bright. "John's achievements are clearly demonstrated by the advancements he and the InStatin team have made with their novel inhaled statin solution for treating and managing chronic lung conditions, such as asthma and chronic obstructive pulmonary disease (COPD). We're honored to be working with such a well-respected and recognized leader in the space, who has achieved several successful M&A exits."
"我们非常高兴地祝贺John荣获这项当之无愧的杰出奖项,表彰他在呼吸道药物传递(RDD)系统方面的卓越贡献," Therma Bright首席执行官Rob Fia表示。"John和InStatin团队在他们治疗和管理哮喘和慢性阻塞性肺部疾病等慢性肺部疾病方面取得的进展,充分证明了他的成就。我们很荣幸能与这个领域内备受尊敬和认可的领导者合作,他已实现了多次成功的并购退出。"
InStatin's innovative statin inhalant solution has shown promising results in laboratory tests, and the Company is now moving forward with preclinical studies in preparation for Phase 1 human trials. Both InStatin and its investment partner, Therma Bright, are enthusiastic about the potential success of this groundbreaking inhalant solution for asthma treatment, which is projected to reach a global market size of USD $30.1 billion by 2030, according to BioSpace news. Therma Bright owns 17% in InStatin with the SAFE investment increasing the Company's ownership in the future at a discount to the next round of financing secured by InStatin.
稳定科技的创新他汀吸入式溶液在实验室测试中显示出有希望的结果,该公司现已开始进行临床前研究,为第一阶段人体试验做准备。稳定科技以及其投资伙伴Therma Bright,对于这种突破性的用于哮喘治疗的吸入式溶液的潜在成功都充满了热情,根据BioSpace新闻,该产品预计将在2030年达到301亿美元的全球市场规模。Therma Bright目前持有InStatin 17%的股份,并在未来通过SAFE投资以折扣价格增加对InStatin的所有权,该SAFE投资是在InStatin获得下一轮融资时获得的。
Additionally, Therma Bright and InStatin are progressing forward with InVixa, which is developing inhaled statins to prevent and treat acute lung disease. As announced on September 27, 2023, Therma Bright holds over 60% of InVixa shares.
此外,Therma Bright和InStatin正推进InVixa的研发工作,该项目正在研发吸入式他汀类药物以预防和治疗急性肺疾病。根据2023年9月27日公布的消息,Therma Bright持有InVixa超过60%的股份。
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
Therma Bright Inc.简介:Therma Bright是一家开发商和合作伙伴,在各种领先的专有诊断和医疗器械技术方面致力于为消费者和医疗专业人士提供质量卓越,创新的解决方案,以应对当今最重要的医疗和医疗保健挑战。在TSXV:THRM,OTCQB:TBRIF,FSE:JNX上交易。访问:。
Therma Bright Inc.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
Rob Fia,首席执行官
rfia@thermabright.com
rfia@thermabright.com
关注我们的Twitter账号
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as progressing clinical trials at InStatin, and related information as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-Looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
前瞻性声明
此新闻发布中的某些陈述构成“前瞻”陈述。这些陈述涉及将在InStatin进行的临床试验,以及新闻发布中所述的相关信息。所有这些陈述都涉及重大已知和未知的风险、不确定性和其他因素,这些因素可能导致实际结果与此类前瞻性陈述所表达或暗示的结果不同。前瞻性陈述涉及重大风险和不确定性,不应被视为对未来业绩或结果的保证,并不一定准确表明是否将实现这些结果。实际结果可能因多种因素和风险而有所不同。尽管本新闻发布中的前瞻性陈述是基于公司管理层在本新闻发布日所认为的合理假设,但公司无法保证实际结果与这些前瞻性陈述一致。本新闻发布中的前瞻性陈述是截至本文发出之日所作,除非根据适用证券监管法规的要求,否则公司不承担更新或修订任何前瞻性陈述的意图或责任。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
TSX Venture Exchange及其监管服务提供商(如TSX Venture Exchange政策中所定义)对本新闻稿的充分性或准确性不承担责任。